Novo Nordisk, a global healthcare company and leader in diabetes care, today announced the launch of the Novo Nordisk BlueSheet, a resource for information on diabetes and chronic disease, highlighting key issues in diabetes prevention, detection, treatment and care.
The first issue of the Novo Nordisk BlueSheet examines how legislation, advocacy and research can help change the way diabetes is funded and treated in the U.S. today. Each quarter, the Novo Nordisk BlueSheet will highlight key issues in diabetes from innovation in patient care to government investment in prevention and care to public education.
To read the Novo Nordisk BlueSheet, go to: http://press.novonordisk-us.com/bluesheet.
"Novo Nordisk is dedicated to changing how diabetes is treated, how it is viewed, and how the disease evolves in the future. But we cannot do it alone," said Jerzy Gruhn, president, Novo Nordisk Inc. "By stimulating a public dialog, we hope to act as a catalyst for change by encouraging action, influencing legislative policy and building advocacy for the prevention, detection, treatment and care of diabetes around the world."
Anti-inflammatory cytokine linked to capillary obstruction and cognitive decline in diabetes